Related Experiment Video

Updated: Jun 1, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic viruses for the treatment of neuroendocrine tumors

M Essand1, J Leja, V Giandomenico

  • 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden. magnus.essand@igp.uu.se

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|June 1, 2011
PubMed

Insights

Oncolytic viruses show promise for treating neuroendocrine tumors by selectively replicating in and killing cancer cells. These viruses offer advantages over traditional therapies, including self-replication and immune system activation.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Oncolytic viruses are a novel class of anticancer agents.
  • Neuroendocrine tumors (NETs) represent a significant challenge in cancer therapy.
  • Viruses possess natural or engineered tumor-targeting capabilities.

Purpose of the Study:

  • To review the current literature on oncolytic virus applications in neuroendocrine tumors.
  • To highlight the therapeutic potential and advantages of oncolytic viruses for NETs.
  • To identify future research directions in this field.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of viral tropism, genetic engineering, and therapeutic mechanisms.
  • Evaluation of viral advantages over conventional treatments.

Main Results:

  • Oncolytic viruses demonstrate selective replication and tumor cell lysis.
  • Advantages include in-situ dose escalation, immunogenicity, and overcoming drug resistance.
  • Potential to modify the tumor microenvironment and activate anti-tumor immunity.

Conclusions:

  • Oncolytic viruses are a promising therapeutic strategy for neuroendocrine tumors.
  • Further research is needed to optimize their use and overcome challenges.
  • Future directions include exploring novel viral vectors and combination therapies.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...